Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances.

Frontiers in endocrinology

Bordier L, Dolz M, Monteiro L, Névoret ML, Calvet JH, Bauduceau B.
PMID: 26973597
Front Endocrinol (Lausanne). 2016 Feb 29;7:18. doi: 10.3389/fendo.2016.00018. eCollection 2016.

No abstract available.

Cite
Bordier L, Dolz M, Monteiro L, et al. Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances. Front Endocrinol (Lausanne). 2016;7:18doi: 10.3389/fendo.2016.00018.
Bordier, L., Dolz, M., Monteiro, L., Névoret, M. L., Calvet, J. H., & Bauduceau, B. (2016). Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances. Frontiers in endocrinology, 718. https://doi.org/10.3389/fendo.2016.00018
Bordier, Lyse, et al. "Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances." Frontiers in endocrinology vol. 7 (2016): 18. doi: https://doi.org/10.3389/fendo.2016.00018
Bordier L, Dolz M, Monteiro L, Névoret ML, Calvet JH, Bauduceau B. Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances. Front Endocrinol (Lausanne). 2016 Feb 29;7:18. doi: 10.3389/fendo.2016.00018. eCollection 2016. PMID: 26973597; PMCID: PMC4770015.
Copy Download .nbib Format: NLM
Association Between the .

Diabetes care

Mohammedi K, Abouleka Y, Carpentier C, Potier L, Dubois S, Foussard N, Rigalleau V, Gautier JF, Gourdy P, Charpentier G, Roussel R, Scheen A, Bauduceau B, Hadjadj S, Alhenc-Gelas F, Marre M, Velho G.
PMID: 34853028
Diabetes Care. 2021 Dec 01; doi: 10.2337/dc21-0973. Epub 2021 Dec 01.

RESULTS: Among 1,301 participants (male 54%, age 41 ± 13 years), 90 (6.9%) had a baseline history of LLA. Baseline LLA was more prevalent in XD (7.4%) than in II genotype (4.5%, odds ratio [OR] 2.17 [95%CI 1.03-4.60]). Incident...

Cite
Mohammedi K, Abouleka Y, Carpentier C, et al. Association Between the . Diabetes Care. 2021;doi: 10.2337/dc21-0973.
Mohammedi, K., Abouleka, Y., Carpentier, C., Potier, L., Dubois, S., Foussard, N., Rigalleau, V., Gautier, J. F., Gourdy, P., Charpentier, G., Roussel, R., Scheen, A., Bauduceau, B., Hadjadj, S., Alhenc-Gelas, F., Marre, M., & Velho, G. (2021). Association Between the . Diabetes care, . https://doi.org/10.2337/dc21-0973
Mohammedi, Kamel, et al. "Association Between the ." Diabetes care vol. (2021). doi: https://doi.org/10.2337/dc21-0973
Mohammedi K, Abouleka Y, Carpentier C, Potier L, Dubois S, Foussard N, Rigalleau V, Gautier JF, Gourdy P, Charpentier G, Roussel R, Scheen A, Bauduceau B, Hadjadj S, Alhenc-Gelas F, Marre M, Velho G. Association Between the . Diabetes Care. 2021 Dec 01; doi: 10.2337/dc21-0973. Epub 2021 Dec 01. PMID: 34853028.
Copy Download .nbib Format: NLM
Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome?.

Metabolic syndrome and related disorders

Garcin JM, Cremades S, Garcia-Hejl C, Bordier L, Dupuy O, Mayaudon H, Bauduceau B.
PMID: 18370737
Metab Syndr Relat Disord. 2006;4(3):185-95. doi: 10.1089/met.2006.4.185.

The aim of this study was to ascertain if hyperhomocysteinemia is associated with the metabolic syndrome. The metabolic syndrome is a cluster of cardiovascular risk factors. Hyperhomocysteinemia is an obvious independent risk factor for atheroma, and thrombosis morbidity and...

Cite
Garcin JM, Cremades S, Garcia-Hejl C, et al. Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome?. Metab Syndr Relat Disord. 2006;4(3):185-95doi: 10.1089/met.2006.4.185.
Garcin, J. M., Cremades, S., Garcia-Hejl, C., Bordier, L., Dupuy, O., Mayaudon, H., & Bauduceau, B. (2006). Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome?. Metabolic syndrome and related disorders, 4(3), 185-95. https://doi.org/10.1089/met.2006.4.185
Garcin, J-M, et al. "Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome?." Metabolic syndrome and related disorders vol. 4,3 (2006): 185-95. doi: https://doi.org/10.1089/met.2006.4.185
Garcin JM, Cremades S, Garcia-Hejl C, Bordier L, Dupuy O, Mayaudon H, Bauduceau B. Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome?. Metab Syndr Relat Disord. 2006;4(3):185-95. doi: 10.1089/met.2006.4.185. PMID: 18370737.
Copy Download .nbib Format: NLM
Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.

Diabetologia

Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, Amadou C, Arnault G, Baudoux F, Bauduceau B, Borot S, Bourgeon-Ghittori M, Bourron O, Boutoille D, Cazenave-Roblot F, Chaumeil C, Cosson E, Coudol S, Darmon P, Disse E, Ducet-Boiffard A, Gaborit B, Joubert M, Kerlan V, Laviolle B, Marchand L, Meyer L, Potier L, Prevost G, Riveline JP, Robert R, Saulnier PJ, Sultan A, Thébaut JF, Thivolet C, Tramunt B, Vatier C, Roussel R, Gautier JF, Gourdy P.
PMID: 32617649
Diabetologia. 2020 Sep;63(9):1953-1957. doi: 10.1007/s00125-020-05207-3.

The authors regret a mistake in Table 1.

Cite
Cariou B, Hadjadj S, Wargny M, et al. Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(9):1953-1957doi: 10.1007/s00125-020-05207-3.
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al-Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., Borot, S., Bourgeon-Ghittori, M., Bourron, O., Boutoille, D., Cazenave-Roblot, F., Chaumeil, C., Cosson, E., Coudol, S., Darmon, P., Disse, E., Ducet-Boiffard, A., Gaborit, B., Joubert, M., Kerlan, V., Laviolle, B., Marchand, L., Meyer, L., Potier, L., Prevost, G., Riveline, J. P., Robert, R., Saulnier, P. J., Sultan, A., Thébaut, J. F., Thivolet, C., Tramunt, B., Vatier, C., Roussel, R., Gautier, J. F., Gourdy, P. (2020). Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia, 63(9), 1953-1957. https://doi.org/10.1007/s00125-020-05207-3
Cariou, Bertrand, et al. "Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study." Diabetologia vol. 63,9 (2020): 1953-1957. doi: https://doi.org/10.1007/s00125-020-05207-3
Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, Amadou C, Arnault G, Baudoux F, Bauduceau B, Borot S, Bourgeon-Ghittori M, Bourron O, Boutoille D, Cazenave-Roblot F, Chaumeil C, Cosson E, Coudol S, Darmon P, Disse E, Ducet-Boiffard A, Gaborit B, Joubert M, Kerlan V, Laviolle B, Marchand L, Meyer L, Potier L, Prevost G, Riveline JP, Robert R, Saulnier PJ, Sultan A, Thébaut JF, Thivolet C, Tramunt B, Vatier C, Roussel R, Gautier JF, Gourdy P. Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020 Sep;63(9):1953-1957. doi: 10.1007/s00125-020-05207-3. PMID: 32617649; PMCID: PMC7330254.
Copy Download .nbib Format: NLM
Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group.

BJR open

Scher N, Bauduceau O, Bollet M, Lamallem H, Charas T, Garaud P, Foster D, Fawzi M, Labidi M, Toledano A.
PMID: 33178921
BJR Open. 2019 Jun 07;1(1):20180027. doi: 10.1259/bjro.20180027. eCollection 2019.

OBJECTIVE: Our objective was to report our experience and to evaluate the feasibility and toxicity of focal salvage stereotactic body radiation therapy (SBRT) in patients with post-radiation local recurrence of prostate cancer.METHODS: We retrospectively reviewed medical records of patients...

Cite
Scher N, Bauduceau O, Bollet M, et al. Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group. BJR Open. 2019;1(1):20180027doi: 10.1259/bjro.20180027.
Scher, N., Bauduceau, O., Bollet, M., Lamallem, H., Charas, T., Garaud, P., Foster, D., Fawzi, M., Labidi, M., & Toledano, A. (2019). Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group. BJR open, 1(1), 20180027. https://doi.org/10.1259/bjro.20180027
Scher, Nathaniel, et al. "Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group." BJR open vol. 1,1 (2019): 20180027. doi: https://doi.org/10.1259/bjro.20180027
Scher N, Bauduceau O, Bollet M, Lamallem H, Charas T, Garaud P, Foster D, Fawzi M, Labidi M, Toledano A. Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group. BJR Open. 2019 Jun 07;1(1):20180027. doi: 10.1259/bjro.20180027. eCollection 2019. PMID: 33178921; PMCID: PMC7592466.
Copy Download .nbib Format: NLM
Granulocytic sarcoma in a nonleukemic patient: place of radiotherapy and systemic therapies.

Case reports in medicine

Chargari C, Jacob J, Bauduceau O, Ferrand FR, De Revel T, Védrine L.
PMID: 21629817
Case Rep Med. 2011;2011:929161. doi: 10.1155/2011/929161. Epub 2011 May 10.

Granulocytic sarcoma is a rare extramedullary tumour, which most often occurs in the course of an acute or chronic leukaemia or myeloproliferative disorders. Rarely it is found before peripheral blood or bone marrow evidence of leukemia is present. We...

Cite
Chargari C, Jacob J, Bauduceau O, et al. Granulocytic sarcoma in a nonleukemic patient: place of radiotherapy and systemic therapies. Case Rep Med. 2011;2011:929161doi: 10.1155/2011/929161.
Chargari, C., Jacob, J., Bauduceau, O., Ferrand, F. R., De Revel, T., & Védrine, L. (2011). Granulocytic sarcoma in a nonleukemic patient: place of radiotherapy and systemic therapies. Case reports in medicine, 2011929161. https://doi.org/10.1155/2011/929161
Chargari, C, et al. "Granulocytic sarcoma in a nonleukemic patient: place of radiotherapy and systemic therapies." Case reports in medicine vol. 2011 (2011): 929161. doi: https://doi.org/10.1155/2011/929161
Chargari C, Jacob J, Bauduceau O, Ferrand FR, De Revel T, Védrine L. Granulocytic sarcoma in a nonleukemic patient: place of radiotherapy and systemic therapies. Case Rep Med. 2011;2011:929161. doi: 10.1155/2011/929161. Epub 2011 May 10. PMID: 21629817; PMCID: PMC3099229.
Copy Download .nbib Format: NLM
Pancreatic metastasis from prostate cancer.

Case reports in medicine

Jacob J, Chargari C, Bauduceau O, Fayolle M, Ceccaldi B, Prat F, Le Moulec S, Vedrine L.
PMID: 20508841
Case Rep Med. 2010;2010:826273. doi: 10.1155/2010/826273. Epub 2010 May 23.

The pancreas is an unusual location for metastases from other primary cancers. Rarely, pancreatic metastases from kidney or colorectal cancers have been reported. However, a variety of other cancers may also spread to the pancreas. We report an exceptional...

Cite
Jacob J, Chargari C, Bauduceau O, et al. Pancreatic metastasis from prostate cancer. Case Rep Med. 2010;2010:826273doi: 10.1155/2010/826273.
Jacob, J., Chargari, C., Bauduceau, O., Fayolle, M., Ceccaldi, B., Prat, F., Le Moulec, S., & Vedrine, L. (2010). Pancreatic metastasis from prostate cancer. Case reports in medicine, 2010826273. https://doi.org/10.1155/2010/826273
Jacob, Julian, et al. "Pancreatic metastasis from prostate cancer." Case reports in medicine vol. 2010 (2010): 826273. doi: https://doi.org/10.1155/2010/826273
Jacob J, Chargari C, Bauduceau O, Fayolle M, Ceccaldi B, Prat F, Le Moulec S, Vedrine L. Pancreatic metastasis from prostate cancer. Case Rep Med. 2010;2010:826273. doi: 10.1155/2010/826273. Epub 2010 May 23. PMID: 20508841; PMCID: PMC2874928.
Copy Download .nbib Format: NLM
Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.

Annales d'endocrinologie

Le Pen C, Bauduceau B, Ansolabehere X, Troubat A, Bineau S, Ripert M, Dejager S.
PMID: 33417963
Ann Endocrinol (Paris). 2021 Apr;82(2):99-106. doi: 10.1016/j.ando.2020.12.009. Epub 2021 Jan 05.

BACKGROUND: Different countries have their own systems for evaluating new medicines, and they make decisions as to when and how each new medicine is adopted.PURPOSE: To compare the rate of uptake of new diabetes medicines (dipeptidyl peptidase-4 inhibitors [DPP-4Is],...

Cite
Le Pen C, Bauduceau B, Ansolabehere X, et al. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes. Ann Endocrinol (Paris). 2021;82(2):99-106doi: 10.1016/j.ando.2020.12.009.
Le Pen, C., Bauduceau, B., Ansolabehere, X., Troubat, A., Bineau, S., Ripert, M., & Dejager, S. (2021). Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes. Annales d'endocrinologie, 82(2), 99-106. https://doi.org/10.1016/j.ando.2020.12.009
Le Pen, Claude, et al. "Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes." Annales d'endocrinologie vol. 82,2 (2021): 99-106. doi: https://doi.org/10.1016/j.ando.2020.12.009
Le Pen C, Bauduceau B, Ansolabehere X, Troubat A, Bineau S, Ripert M, Dejager S. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes. Ann Endocrinol (Paris). 2021 Apr;82(2):99-106. doi: 10.1016/j.ando.2020.12.009. Epub 2021 Jan 05. PMID: 33417963.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries